1. Generics Bulletin
  2. >>Products

Five Things Facing Teva’s New CEO Richard Francis

Former Sandoz Head To Take Charge At Teva On 1 January 2023

 
• By Dean Rudge

With Teva clearing up early who will replace outgoing president and CEO Kåre Schultz, Generics Bulletin looks at five issues that await his replacement, the former Sandoz head Richard Francis.

Francis_Richard
Francis brings both generic and branded experience to Teva • Source: Novartis

A new year is on the horizon, bringing a new, recognizable face to the top job at Teva. Four years after departing from rival Sandoz, Richard Francis is once again to take the CEO role at one of the generics and biosimilars industry’s leading players.

Francis will swap gene therapy for generics when he officially takes up the mantle at Teva on 1 January – some ten months ahead of incumbent Kåre Schultz’s current contract expiring, with Schultz now set to step down at the end of 2022

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.